| __timestamp | Arrowhead Pharmaceuticals, Inc. | Dr. Reddy's Laboratories Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 38783000000 |
| Thursday, January 1, 2015 | 34718089 | 42585000000 |
| Friday, January 1, 2016 | 40998209 | 45702000000 |
| Sunday, January 1, 2017 | 32022880 | 46372000000 |
| Monday, January 1, 2018 | 19110051 | 46910000000 |
| Tuesday, January 1, 2019 | 26556257 | 48890000000 |
| Wednesday, January 1, 2020 | 52275890 | 50129000000 |
| Friday, January 1, 2021 | 80981000 | 54559000000 |
| Saturday, January 1, 2022 | 124431000 | 62081000000 |
| Sunday, January 1, 2023 | 90932000 | 105931000000 |
| Monday, January 1, 2024 | 98761000 | 77201000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding spending patterns is crucial. Dr. Reddy's Laboratories Limited and Arrowhead Pharmaceuticals, Inc. offer a fascinating study in contrasts. From 2014 to 2024, Dr. Reddy's Laboratories consistently allocated a significant portion of its budget to Selling, General, and Administrative (SG&A) expenses, peaking at over $105 billion in 2023. This represents a staggering 172% increase from 2014. In contrast, Arrowhead Pharmaceuticals, while showing growth, maintained a more modest trajectory, with SG&A expenses rising from approximately $24 million in 2014 to nearly $99 million in 2024, marking a 308% increase. This divergence highlights differing strategic priorities: Dr. Reddy's focuses on expansive market penetration, while Arrowhead emphasizes targeted innovation. As the pharmaceutical industry continues to grow, these spending patterns offer insights into each company's strategic direction and market positioning.
Selling, General, and Administrative Costs: AbbVie Inc. vs Arrowhead Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dr. Reddy's Laboratories Limited
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Dr. Reddy's Laboratories Limited or Exelixis, Inc.
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Lantheus Holdings, Inc. Trends and Insights
Dr. Reddy's Laboratories Limited vs CRISPR Therapeutics AG: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Galapagos NV
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Ascendis Pharma A/S and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
ADMA Biologics, Inc. vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared